Ascendis Pharma A/S - Ordinary Share (ASND)
ASND moved a median of -0.08% 30 minutes after news, and +0.36% by the close. How ASND actually reacts to news — the realized, point-in-time move the market made, measured across 474 labeled events over the last three years with zero look-ahead.
ASND’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 49% | 472 |
| 30-min | -0.08% | 48% | 474 |
| 60-min | +0.15% | 53% | 474 |
| to close | +0.36% | 57% | 470 |
| Middle 50% of ASND reactions | -0.94% to +0.73% |
|---|---|
| Median reaction (30-min) | -0.08% |
| Measured reactions | 474 |
Half of all Ascendis Pharma A/S - Ordinary Share news events land between -0.94% and +0.73% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ASND reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 22 | +0.07% | 50% | -0.74% |
| Coverage initiations | 32 | -0.02% | 50% | -0.15% |
| Rating reiterations | 149 | +0.12% | 56% | +0.22% |
| Price-target raises | 49 | -0.07% | 43% | +0.45% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how ASND ranks against every other measured name →
That’s how ASND usually reacts — get an email when it moves on news →Email me when ASND moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ASND's baseline. Nothing else.
Recent ASND events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026 | Press release | GlobeNewswire | -0.35% | -1.38% | |
| Form 6-K Ascendis Pharma A/S For: Sep 29 | SEC filing · Form 6-K | SEC EDGAR | -0.07% | -0.06% | |
| Form 6-K Ascendis Pharma A/S For: Sep 14 | SEC filing · Form 6-K | SEC EDGAR | -5.38% | -6.43% | |
| Ascendis Announces Planned $400 Million Share Repurchase Program | Press release | GlobeNewswire | -5.38% | -6.43% | |
| Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases | Press release | GlobeNewswire | -5.38% | -6.43% | |
| First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026 | Press release | GlobeNewswire | +0.41% | +0.47% | |
| Form 6-K Ascendis Pharma A/S For: Sep 09 | SEC filing · Form 6-K | SEC EDGAR | +0.41% | +0.47% | |
| Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference | Press release | GlobeNewswire | -0.25% | -2.94% | |
| Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026 | Press release | GlobeNewswire | +0.53% | +2.54% | |
| Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL® (Navepegritide) | Press release | GlobeNewswire | +1.02% | +6.21% | |
| Form 6-K Ascendis Pharma A/S For: Aug 31 | SEC filing · Form 6-K | SEC EDGAR | +1.42% | -0.54% | |
| Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026 | Press release | GlobeNewswire | -0.94% | -1.02% | |
| Eyconis Announces Initiation of First-in-Human Clinical Trial of EYC-0305 in Treatment-Naïve Wet Age-Related Macular Degeneration Patients | Press release | GlobeNewswire | +0.73% | +0.97% | |
| Ascendis Pharma Reports Second Quarter 2026 Financial Results | Press release | GlobeNewswire | -0.15% | -1.66% | |
| Form 6-K Ascendis Pharma A/S For: Aug 13 | SEC filing · Form 6-K | SEC EDGAR | -0.15% | -1.66% | |
| Form 6-K Ascendis Pharma A/S For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | -0.15% | -1.66% | |
| Form 6-K Ascendis Pharma A/S For: Aug 12 | SEC filing · Form 6-K | SEC EDGAR | -0.15% | -1.66% | |
| Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S. | Press release | GlobeNewswire | +0.36% | +2.10% | |
| Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026 | Press release | GlobeNewswire | +0.66% | +1.45% | |
| Form 6-K Ascendis Pharma A/S For: Aug 06 | SEC filing · Form 6-K | SEC EDGAR | +0.06% | -0.10% | |
| Form 6-K Ascendis Pharma A/S For: Jul 15 | SEC filing · Form 6-K | SEC EDGAR | -0.32% | -2.84% | |
| Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial | Press release | GlobeNewswire | -0.07% | +0.65% | |
| Form 6-K Ascendis Pharma A/S For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | -0.96% | +0.10% | |
| Form 6-K Ascendis Pharma A/S For: Jun 29 | SEC filing · Form 6-K | SEC EDGAR | -0.07% | +0.65% | |
| Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap® | Press release | GlobeNewswire | -1.49% | +0.18% | |
| Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026 | Press release | GlobeNewswire | +1.46% | -0.41% | |
| Form 6-K Ascendis Pharma A/S For: Jun 17 | SEC filing · Form 6-K | SEC EDGAR | +0.27% | -1.19% | |
| Form 6-K Ascendis Pharma A/S For: Jun 15 | SEC filing · Form 6-K | SEC EDGAR | +0.23% | +1.04% | |
| Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism | Press release | GlobeNewswire | +0.23% | +1.04% | |
| Form 6-K Ascendis Pharma A/S For: Jun 12 | SEC filing · Form 6-K | SEC EDGAR | +0.78% | +0.72% | |
| 5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism | Press release | GlobeNewswire | +0.78% | +0.72% | |
| Form 6-K Ascendis Pharma A/S For: Jun 10 | SEC filing · Form 6-K | SEC EDGAR | -0.71% | +2.80% | |
| Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026 | Press release | GlobeNewswire | +0.92% | +2.85% | |
| Form SD Ascendis Pharma A/S | SEC filing · Form SD | SEC EDGAR | -1.26% | -2.26% | |
| Form 6-K Ascendis Pharma A/S For: May 13 | SEC filing · Form 6-K | SEC EDGAR | +0.50% | +0.33% | |
| Ascendis Pharma Reports First Quarter 2026 Financial Results | Press release | GlobeNewswire | +0.67% | +9.40% | |
| Form 6-K Ascendis Pharma A/S For: Mar 31 | SEC filing · Form 6-K | SEC EDGAR | +0.67% | +9.40% | |
| Form 6-K Ascendis Pharma A/S For: May 07 | SEC filing · Form 6-K | SEC EDGAR | +0.67% | +9.40% | |
| New 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged =5 Years | Press release | GlobeNewswire | +0.67% | +9.40% | |
| Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026 | Press release | GlobeNewswire | +0.86% | -3.68% | |
| Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028 | Press release | GlobeNewswire | -0.85% | -1.68% | |
| Form 6-K Ascendis Pharma A/S For: Apr 21 | SEC filing · Form 6-K | SEC EDGAR | -0.77% | -1.99% | |
| Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq | Press release | GlobeNewswire | +1.29% | +0.37% | |
| Form 6-K Ascendis Pharma A/S For: Apr 20 | SEC filing · Form 6-K | SEC EDGAR | +1.29% | +0.37% | |
| Form 8-A12B/A Ascendis Pharma A/S | SEC filing · Form 8-A12B | SEC EDGAR | +1.29% | +0.37% | |
| Form 6-K Ascendis Pharma A/S For: Apr 15 | SEC filing · Form 6-K | SEC EDGAR | -0.67% | +0.51% | |
| Ascendis Pharma to List Ordinary Shares Directly on Nasdaq | Press release | GlobeNewswire | -0.28% | +2.65% | |
| Form 6-K Ascendis Pharma A/S For: Apr 08 | SEC filing · Form 6-K | SEC EDGAR | +0.96% | +3.65% | |
| New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP’s Benefits Beyond Linear Growth in Children with Achondroplasia | Press release | GlobeNewswire | -0.58% | +5.42% | |
| Form 6-K Ascendis Pharma A/S For: Apr 06 | SEC filing · Form 6-K | SEC EDGAR | -0.21% | -0.11% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ASND section they belong to.
Where else ASND is measured.
ASND earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| RXI PHARMACEUTICALS CORP (RXII) | 477 | -1.14% | 32% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 477 | -0.11% | 46% |
| Global Cord Blood Corporation (CO) | 471 | 0.00% | 44% |
| NANTKWEST (NK) | 469 | -0.32% | 42% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Ascendis Pharma A/S - Ordinary Share's median reaction calculated?
Every labeled ASND news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 474 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 48% of ASND's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ASND's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.